VAXIL
Creating the ideal immunotherapy
Inducing a Broad
Response
Learn More
universally
Applicable
Learn More
Overcoming
Cancer Resistance
Learn More
Harnessing Potent
Immune Response
Learn More
Tumor
Specific
Learn More
Expression on
Cancer Stem Cells
Learn More
neo-antigen
acting
Learn More
First-ever SP-Specific
Antibody Platform
Learn More
Vaxil’s Lead Products and Orphan Drug Status
Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™ platform is its Immucin™; lead immunotherapy product. After completion of a successful Phase-I/II in 15 multiple myeloma cancer patients, Vaxil’s Immucin™ was granted Orphan Drug Status by the FDA and EMA for that indication.
Vaxil’s Lead Immunotherapy Immucin™ Obtains Orphan Drug Status from FDA and EMA